KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Tax Provisions: 2016-2024

Historic Tax Provisions for Moderna (MRNA) over the last 9 years, with Dec 2024 value amounting to -$46.0 million.

  • Moderna's Tax Provisions rose 62.50% to $13.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$37.0 million, marking a year-over-year decrease of 102.40%. This contributed to the annual value of -$46.0 million for FY2024, which is 105.96% down from last year.
  • Per Moderna's latest filing, its Tax Provisions stood at -$46.0 million for FY2024, which was down 105.96% from $772.0 million recorded in FY2023.
  • Moderna's Tax Provisions' 5-year high stood at $1.2 billion during FY2022, with a 5-year trough of -$46.0 million in FY2024.
  • For the 3-year period, Moderna's Tax Provisions averaged around $646.3 million, with its median value being $772.0 million (2023).
  • In the last 5 years, Moderna's Tax Provisions surged by 36,000.00% in 2021 and then tumbled by 105.96% in 2024.
  • Yearly analysis of 5 years shows Moderna's Tax Provisions stood at $3.0 million in 2020, then skyrocketed by 36,000.00% to $1.1 billion in 2021, then climbed by 12.00% to $1.2 billion in 2022, then crashed by 36.36% to $772.0 million in 2023, then slumped by 105.96% to -$46.0 million in 2024.